Sydney-based medical solutions provider Device Technologies has bought oncology equipment specialist DTect Innovation.
Device Technologies says the acquisition is aimed at shoring up its offering in the field oncology which it sees as vital in combatting Australia’s “rising cancer rates”.
Founded in 2016 by Peter Douglas, DTect Innovation focuses on nucleonic equipment for detection, measurement, analysis and radiation delivery.
Device Technologies says DTect’s commitment to precision and excellence “seamlessly aligns with Device Technologies' core values of innovation and enhancing patient outcomes”.
“Acquiring DTect Innovation reinforces our commitment to delivering advanced healthcare solutions across the ANZ region,” says Michael Trevaskis, CEO of Device Technologies.
“With over 36 years of expertise in medical physics and radiation detection, DTect is a trusted partner with values and innovations that align seamlessly with our purpose.
“Integrating its technologies into our portfolio will further strengthen our ability to support ANZ healthcare in delivering superior patient outcomes and advancing oncology care.”
Financial details of the acquisition have not been disclosed.
The deal comes on the heels of a raft of acquisitions by Device Technologies over the past year, including wholesale medical supplies companies Atris, CK Surgitech, Denyers International and Venusys Medical, each of which the company says reinforces its mission to deliver best in-class service across the Asia Pacific region.
“This acquisition allows us to expand our reach and support more clinicians, medical physicists and researchers in delivering critical oncology care,” says Douglas, director at DTect Innovation.
“Becoming a part of Device Technologies enhances our ability to not only deliver high quality products, trusted solutions and innovative technologies, but also provide better support for them and those who put their trust in them, to continue improving precision and patient outcomes.
“We’re excited by the opportunities this new chapter brings to transform oncology care across the region.”
Douglas has been involved in the sales of nucleonic equipment since 1985, establishing the Sydney-based DTect Innovation in the wake of the sale in 2016 of a previous joint venture with Dutch company Nucletron BV to Swedish medical equipment group Elekta.
Help us deliver quality journalism to you.
As a free and independent news site providing daily updates
during a period of unprecedented challenges for businesses everywhere
we call on your support